Exosomes for Hair Loss: Evidence and Regulatory Risks
Early exosome research, product variability and the distinction between US regulation and local authorisation.
Biology
Exosomes are a subset of extracellular vesicles. Cell source, purity, contents and dose differ across products.
Research
Cell culture and early human studies investigate potential effects. They do not establish durable efficacy and long-term safety for every marketed product.
FDA safety information
The FDA states that there are no FDA-approved exosome products. This describes US regulation; current Turkish TİTCK requirements must be verified separately.
Patient information
Exosome procedures must not be described as guaranteed hair growth or established stem-cell treatment.
Limits of the evidence
These are selected clinical sources and expert recommendations, not a new systematic review. Formulations, participants, controls, follow-up and adverse-event reporting differ. Positive findings do not establish identical benefit or local authorisation for every patient or product.
Topic-specific questions
Are exosomes the same as living stem cells?
No. Extracellular vesicles and living cellular products are different biological materials.
Does a US regulatory statement establish authorisation in Türkiye?
No. Product-specific local requirements and permissions need separate verification.
Scientific references
- Rosenthal A et al. Management of androgenic alopecia: a systematic review of the literature. J Cosmet Laser Ther. 2024. DOI: 10.1080/14764172.2024.2362126. https://pubmed.ncbi.nlm.nih.gov/38852607/
- US Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes